Bicara, Zenas and MBX rekin­dle IPO mar­ket with rare Fri­day triple­head­er

Af­ter a sleepy few months, the biotech IPO mar­ket is wak­ing up thanks to back-to-back-to-back list­ings.

On­col­o­gy-fo­cused Bicara Ther­a­peu­tics, au­toim­mune start­up Zenas Bio­Phar­ma and meta­bol­ic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER